{"id":24784,"date":"2022-10-31T00:19:00","date_gmt":"2022-10-30T16:19:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24784"},"modified":"2025-02-02T00:25:12","modified_gmt":"2025-02-01T16:25:12","slug":"eli-lilly-cancels-licensing-deal-for-fosun-pharmas-fcn-338","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24784","title":{"rendered":"Eli Lilly Cancels Licensing Deal for Fosun Pharma’s FCN-338"},"content":{"rendered":"\n

Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196<\/a>, HKG: 2196<\/a>) announced that its US partner Eli Lilly has decided to cancel the licensing deal struck with its subsidiary Fochon Pharmaceuticals Ltd in relation to FCN-338, a selective B-cell lymphoma 2 (Bcl-2) small-molecule inhibitor. The decision was cited as a \u201cproduct pipeline strategy adjustment.\u201d<\/p>\n\n\n\n

Original Licensing Agreement<\/strong>
The licensing agreement was initially entered into in October 2020, granting Eli Lilly exclusive development, manufacturing, and commercialization rights to FCN-338 outside of mainland China, Hong Kong, and Macau. Under the terms of the deal, Fosun was to receive USD 40 million upfront, USD 340 million in clinical development milestone payments, and an additional USD 60 million in marketing milestone payments, totaling USD 440 million.<\/p>\n\n\n\n

Competitive Landscape and FCN-338 Development<\/strong>
Several firms are developing next-generation Bcl-2 inhibitors in China, including Ascentage Pharma’s APG-2575, BeiGene’s BGB-11417, and AbbVie’s venetoclax, which was approved in the US market in 2016 and received its first approval in China in December 2020. FCN-338 has obtained clinical trial approvals in both China and the US for the treatment of hematologic malignancies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its US partner…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[234,200,185,30,16,199,3473,159,893,892],"class_list":["post-24784","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-abbvie","tag-ascentage-pharma","tag-beigene","tag-biotech","tag-cancer","tag-eli-lilly","tag-fochon-pharmaceuticals","tag-fosun-pharmaceutical","tag-hkg-2196","tag-sha-600196"],"yoast_head":"\nEli Lilly Cancels Licensing Deal for Fosun Pharma's FCN-338 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its US partner Eli Lilly has decided to cancel the licensing deal struck with its subsidiary Fochon Pharmaceuticals Ltd in relation to FCN-338, a selective B-cell lymphoma 2 (Bcl-2) small-molecule inhibitor. The decision was cited as a \u201cproduct pipeline strategy adjustment.\u201d\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24784\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Cancels Licensing Deal for Fosun Pharma's FCN-338\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24784\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-30T16:19:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-01T16:25:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24784#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24784\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Cancels Licensing Deal for Fosun Pharma’s FCN-338\",\"datePublished\":\"2022-10-30T16:19:00+00:00\",\"dateModified\":\"2025-02-01T16:25:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24784\"},\"wordCount\":188,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AbbVie\",\"Ascentage Pharma\",\"BeiGene\",\"Biotech\",\"Cancer\",\"Eli Lilly\",\"Fochon Pharmaceuticals\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24784#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24784\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24784\",\"name\":\"Eli Lilly Cancels Licensing Deal for Fosun Pharma's FCN-338 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-10-30T16:19:00+00:00\",\"dateModified\":\"2025-02-01T16:25:12+00:00\",\"description\":\"Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its US partner Eli Lilly has decided to cancel the licensing deal struck with its subsidiary Fochon Pharmaceuticals Ltd in relation to FCN-338, a selective B-cell lymphoma 2 (Bcl-2) small-molecule inhibitor. The decision was cited as a \u201cproduct pipeline strategy adjustment.\u201d\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24784#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24784\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24784#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Cancels Licensing Deal for Fosun Pharma’s FCN-338\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Cancels Licensing Deal for Fosun Pharma's FCN-338 - Insight, China's Pharmaceutical Industry","description":"Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its US partner Eli Lilly has decided to cancel the licensing deal struck with its subsidiary Fochon Pharmaceuticals Ltd in relation to FCN-338, a selective B-cell lymphoma 2 (Bcl-2) small-molecule inhibitor. The decision was cited as a \u201cproduct pipeline strategy adjustment.\u201d","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24784","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Cancels Licensing Deal for Fosun Pharma's FCN-338","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24784","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-10-30T16:19:00+00:00","article_modified_time":"2025-02-01T16:25:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24784#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24784"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Cancels Licensing Deal for Fosun Pharma’s FCN-338","datePublished":"2022-10-30T16:19:00+00:00","dateModified":"2025-02-01T16:25:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24784"},"wordCount":188,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AbbVie","Ascentage Pharma","BeiGene","Biotech","Cancer","Eli Lilly","Fochon Pharmaceuticals","Fosun Pharmaceutical","HKG: 2196","SHA: 600196"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24784#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24784","url":"https:\/\/flcube.com\/?p=24784","name":"Eli Lilly Cancels Licensing Deal for Fosun Pharma's FCN-338 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-10-30T16:19:00+00:00","dateModified":"2025-02-01T16:25:12+00:00","description":"Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its US partner Eli Lilly has decided to cancel the licensing deal struck with its subsidiary Fochon Pharmaceuticals Ltd in relation to FCN-338, a selective B-cell lymphoma 2 (Bcl-2) small-molecule inhibitor. The decision was cited as a \u201cproduct pipeline strategy adjustment.\u201d","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24784#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24784"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24784#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Cancels Licensing Deal for Fosun Pharma’s FCN-338"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24784"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24784\/revisions"}],"predecessor-version":[{"id":24785,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24784\/revisions\/24785"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}